GELS — Gelteq Ltd · catalysts, narrative & risks

Snapshot (as of the latest available data, 30 Oct 2026)

Gelteq Limited (NASDAQ: GELS) is a Melbourne-based, U.S.- and Australia-listed micro-cap biotechnology company developing a proprietary gel-based oral delivery platform for human and animal health, operating on a white-label licensing model [3], [15]. As of 30 Oct 2026, the stock traded around $0.49 with a market capitalization of roughly $5.2–5.5M, down ~3% on the day, and trading far below its 52-week high of ~$2.01 [3], [12], [15]. It has essentially no analyst coverage and no price target [3], [15].